Stanley Plokin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9551284/publications.pdf

Version: 2024-02-01

96	8,264	66343	49909
papers	citations	42 h-index	87 g-index

103	103	103	10430
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Correlates of Protection Induced by Vaccination. Vaccine Journal, 2010, 17, 1055-1065.	3.1	1,365
2	Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine, 2021, 39, 4423-4428.	3.8	766
3	Vaccines: Correlates of Vaccineâ€Induced Immunity. Clinical Infectious Diseases, 2008, 47, 401-409.	5.8	693
4	History of vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12283-12287.	7.1	440
5	A Controlled Trial Comparing Vidarabine with Acyclovir in Neonatal Herpes Simplex Virus Infection. New England Journal of Medicine, 1991, 324, 444-449.	27.0	375
6	Nomenclature for Immune Correlates of Protection After Vaccination. Clinical Infectious Diseases, 2012, 54, 1615-1617.	5.8	297
7	Impact of Vaccines; Health, Economic and Social Perspectives. Frontiers in Microbiology, 2020, 11, 1526.	3.5	282
8	Complex Correlates of Protection After Vaccination. Clinical Infectious Diseases, 2013, 56, 1458-1465.	5.8	225
9	The development of vaccines: how the past led to the future. Nature Reviews Microbiology, 2011, 9, 889-893.	28.6	222
10	Immunologic correlates of protection induced by vaccination. Pediatric Infectious Disease Journal, 2001, 20, 63-75.	2.0	215
11	Vaccines: the Fourth Century. Vaccine Journal, 2009, 16, 1709-1719.	3.1	205
12	Protective Effects of Towne Cytomegalovirus Vaccine Against Low-Passage Cytomegalovirus Administered as a Challenge. Journal of Infectious Diseases, 1989, 159, 860-865.	4.0	153
13	Prevention of pertussis: Recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine, 2007, 25, 2634-2642.	3.8	145
14	A Canarypox Vectorâ€“Expressing Cytomegalovirus (CMV) Phosphoprotein 65 Induces Longâ€Lasting Cytotoxic T Cell Responses in Human CMVâ€Seronegative Subjects. Journal of Infectious Diseases, 2001, 183, 1171-1179.	4.0	138
15	Correlates of protection against <scp>SARS</scp>â€<scp>CoV</scp>â€2 infection and COVIDâ€19 disease. Immunological Reviews, 2022, 310, 6-26.	6.0	138
16	Priorities for CMV vaccine development. Vaccine, 2013, 32, 4-10.	3.8	122
17	Strategies to Decrease Pertussis Transmission to Infants. Pediatrics, 2015, 135, e1475-e1482.	2.1	120
18	Updates on immunologic correlates of vaccine-induced protection. Vaccine, 2020, 38, 2250-2257.	3.8	119

#	Article	IF	Citations
19	Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine, 2022, 40, 306-315.	3.8	107
20	The History of Rubella and Rubella Vaccination Leading to Elimination. Clinical Infectious Diseases, 2006, 43, S164-S168.	5.8	97
21	Complex immune correlates of protection in <scp>HIV</scp>â€1 vaccine efficacy trials. Immunological Reviews, 2017, 275, 245-261.	6.0	95
22	The Pertussis Problem. Clinical Infectious Diseases, 2014, 58, 830-833.	5.8	93
23	Vaccination against the human cytomegalovirus. Vaccine, 2019, 37, 7437-7442.	3.8	92
24	What Is Wrong with Pertussis Vaccine Immunity?. Cold Spring Harbor Perspectives in Biology, 2017, 9, a029454.	5.5	82
25	Establishing a Global Vaccine-Development Fund. New England Journal of Medicine, 2015, 373, 297-300.	27.0	79
26	Vaccines, Vaccination, and Vaccinology. Journal of Infectious Diseases, 2003, 187, 1349-1359.	4.0	76
27	Enveloped Virus-Like Particle Expression of Human Cytomegalovirus Glycoprotein B Antigen Induces Antibodies with Potent and Broad Neutralizing Activity. Vaccine Journal, 2014, 21, 174-180.	3.1	74
28	Rubella persistence in epidermal keratinocytes and granuloma M2 macrophages in patients with primary immunodeficiencies. Journal of Allergy and Clinical Immunology, 2016, 138, 1436-1439.e11.	2.9	73
29	The Status of Vaccine Development Against the Human Cytomegalovirus. Journal of Infectious Diseases, 2020, 221, S113-S122.	4.0	73
30	Global incidence of serogroup B invasive meningococcal disease: a systematic review. Lancet Infectious Diseases, The, 2015, 15, 1334-1346.	9.1	71
31	New Vaccines against Epidemic Infectious Diseases. New England Journal of Medicine, 2017, 376, 610-613.	27.0	70
32	The history of vaccination against cytomegalovirus. Medical Microbiology and Immunology, 2015, 204, 247-254.	4.8	62
33	Extraordinary diseases require extraordinary solutions. Vaccine, 2020, 38, 3987-3988.	3.8	62
34	Advancing Our Understanding of Protective Maternal Immunity as a Guide for Development of Vaccines To Reduce Congenital Cytomegalovirus Infections. Journal of Virology, 2018, 92, .	3.4	60
35	Enhancement of Vaginal Infection in Mice by Herpes Simplex Virus Type II with Progesterone. Experimental Biology and Medicine, 1978, 158, 131-134.	2.4	58
36	Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies. PLoS Pathogens, 2019, 15, e1008080.	4.7	58

#	Article	IF	Citations
37	Correlates of protection for enteric vaccines. Vaccine, 2017, 35, 3355-3363.	3.8	54
38	Correcting a Public Health Fiasco: The Need for a New Vaccine against Lyme Disease. Clinical Infectious Diseases, 2011, 52, s271-s275.	5.8	50
39	Protective Immunity and New Vaccines for Lyme Disease. Clinical Infectious Diseases, 2020, 70, 1768-1773.	5.8	50
40	A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirusâ€"Seronegative Men. Journal of Infectious Diseases, 2016, 214, 1341-1348.	4.0	44
41	Vaccines for epidemic infections and the role of CEPI. Human Vaccines and Immunotherapeutics, 2017, 13, 2755-2762.	3.3	44
42	Considering Mandatory Vaccination of Children for COVID-19. Pediatrics, 2021, 147, .	2.1	38
43	White Paper on studying the safety of the childhood immunization schedule in the Vaccine Safety Datalink. Vaccine, 2016, 34, A1-A29.	3.8	35
44	A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes. Hum Vaccin, 2010, 6, 841-848.	2.4	30
45	Recommendations to control pertussis prioritized relative to economies: A Global Pertussis Initiative update. Vaccine, 2018, 36, 7270-7275.	3.8	28
46	Commentary. Pediatric Infectious Disease Journal, 2013, 32, 381-382.	2.0	24
47	Responding to The River. Science, 1999, 286, 2449d-2449.	12.6	23
48	Rubella Eradication: Not Yet Accomplished, but Entirely Feasible. Journal of Infectious Diseases, 2021, 224, S360-S366.	4.0	22
49	The changing epidemiology of mumps in a high vaccination era. Lancet Infectious Diseases, The, 2019, 19, 118-119.	9.1	20
50	Whither vaccines?. Journal of Infection, 2017, 74, S2-S9.	3.3	19
51	The National Vaccine Injury Compensation Program. JAMA - Journal of the American Medical Association, 2019, 321, 343.	7.4	19
52	The science of vaccine safety: Summary of meeting at Wellcome Trust. Vaccine, 2020, 38, 1869-1880.	3.8	19
53	Ten yearly yellow fever booster vaccinations may still be justified. Journal of Travel Medicine, 2018, 25, .	3.0	18
54	Influenza in Latin America: A report from the Global Influenza Initiative (GII). Vaccine, 2019, 37, 2670-2678.	3.8	17

#	Article	IF	Citations
55	Preventing Infection by Human Cytomegalovirus. Journal of Infectious Diseases, 2020, 221, S123-S127.	4.0	16
56	Mumps: A Pain in the Neck. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 91-92.	1.3	15
57	Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers. Clinical Infectious Diseases, 2021, 72, 2035-2041.	5.8	15
58	New Rotavirus Vaccines. Pediatric Infectious Disease Journal, 2006, 25, 575-576.	2.0	12
59	Third Dose of MMR Vaccine for Mumps Control. New England Journal of Medicine, 2017, 377, 2402-2403.	27.0	12
60	The RV144 Thai HIV vaccine trial. Hum Vaccin, 2010, 6, 157-163.	2.4	11
61	Human capital gaps in vaccine development: an issue for global vaccine development and global health. Annals of the New York Academy of Sciences, 2017, 1395, 3-11.	3.8	10
62	Measles: Breakouts and Breakthroughs. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 289-290.	1.3	10
63	Accelerate Coronavirus Disease 2019 (COVID-19) Vaccine Rollout by Delaying the Second Dose of mRNA Vaccines. Clinical Infectious Diseases, 2021, 73, 1320-1321.	5.8	10
64	The influence of interval between doses on response to vaccines. Vaccine, 2021, 39, 7123-7127.	3.8	9
65	Pertussis: pertussis control strategies and the options for improving current vaccines. Expert Review of Vaccines, 2014, 13, 1071-1072.	4.4	8
66	Is There a Correlate of Protection for Measles Vaccine?. Journal of Infectious Diseases, 2020, 221, 1571-1572.	4.0	8
67	The New Coronavirus, the Current King of China. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 1-2.	1.3	8
68	Delayed type hypersensitivity to human cytomegalovirus. Journal of Medical Virology, 1993, 39, 109-117.	5.0	6
69	Vaccines We Need But Don't Have. Viral Immunology, 2018, 31, 114-116.	1.3	6
70	Seroconversion for Cytomegalovirus Infection During Pregnancy and Fetal Infection in a Highly Seropositive Population: â€œThe BraCHS Study,â€•by Mussi-Pinhata et al. Journal of Infectious Diseases, 2018, 218, 1188-1190.	4.0	6
71	A hepatitis B vaccine with a novel adjuvant. Vaccine, 2013, 31, 5297-5299.	3.8	5
72	Commentary: In Memoriam: Hilary Koprowski, 1916â€“2013. Journal of Virology, 2013, 87, 8270-8271.	3.4	5

#	Article	IF	Citations
73	COVID vaccine efficacy against the B.1.351 (â€œSouth Africanâ€) variantâ€”The urgent need to lay the groundwork for possible future challenge studies. Human Vaccines and Immunotherapeutics, 2021, , 1-2.	3.3	5
74	Reply to Gantt et al., â€œHigher Expectations for a Vaccine To Prevent Congenital Cytomegalovirus Infectionâ€. Journal of Virology, 2018, 92, .	3.4	4
75	Dengue Vaccine, A Double-Edged Sword. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 107-109.	1.3	4
76	The scourge of vaccine falsification. Vaccine, 2022, 40, 2126-2128.	3.8	4
77	Problems in Vaccine Development. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2014, 33, 166-167.	1.6	3
78	Vaccines in the 21st Century. Hybridoma, 2002, 21, 135-145.	0.4	2
79	Vaccine mandates in France will save lives. Science, 2018, 359, 283-284.	12.6	2
80	The Influenza Vaccine Mess. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 178-180.	1.3	2
81	What have we learned from the COVID-19 plague?. Science Translational Medicine, 2021, 13, eabl9098.	12.4	2
82	Half-Dose Immunization for Diphtheria, Tetanus, Pertussis. Pediatrics, 1990, 86, 145-145.	2.1	2
83	The virus susceptibility of skin-derived fibroblasts from families with insulin-dependent diabetes mellitus. Journal of Medical Virology, 1982, 9, 281-292.	5.0	1
84	Important New Resource for Clinicians Giving Expert Witness Testimony on Vaccines. Pediatric Infectious Disease Journal, 2018, 37, e353-e353.	2.0	1
85	Portait of an ISV fellow. Human Vaccines and Immunotherapeutics, 2018, 14, 1836-1839.	3.3	1
86	Lemons and Lyme. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 267-269.	1.3	1
87	How to Prepare for Expert Testimony on the Safety of Vaccination. Pediatrics, 2019, 143, e20183578.	2.1	1
88	Chikungunya Virus: A Back-Breaking Problem. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 95-96.	1.3	1
89	Tetanus and Diphtheria Boosters. Clinical Infectious Diseases, 2020, 71, 3266-3267.	5.8	1
90	Dengue vaccines: the road to failure or to success?. Human Vaccines and Immunotherapeutics, 2020, 16, 2677-2679.	3.3	1

#	Article	IF	Citations
91	Titerphilia - The Irresistible Urge to Measure Postimmunization Antibody Values. Pediatric Infectious Disease Journal, 2022, 41, 490-491.	2.0	1
92	The enemy is sometimes us. Hum Vaccin, 2010, 6, 282-282.	2.4	0
93	In Memoriam. Human Vaccines and Immunotherapeutics, 2012, 8, 1321-1322.	3.3	0
94	The History of Vaccines.org publishes a book. Vaccine, 2013, 31, 4697.	3.8	0
95	Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 517-518.	1.3	0
96	Obituary of Robert Daum - Expert in Staphylococcal Disease. Human Vaccines and Immunotherapeutics, 2022, 18, 1.	3.3	0